Bruce Keyt Sells 10,000 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock
Bruce Keyt Sells 10,000 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock
IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) insider Bruce Keyt sold 10,000 shares of IGM Biosciences stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $19.78, for a total transaction of $197,800.00. Following the sale, the insider now owns 39,489 shares of the company's stock, valued at $781,092.42. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
IGM生物科學公司(納斯達克代碼:IGMS-GET Rating)內部人士Bruce KEYT在9月8日星期四的一筆交易中出售了10,000股IGM生物科學公司的股票。這些股票以19.78美元的平均價格出售,總成交金額為197,800.00美元。出售後,這位內部人士現在持有該公司39,489股股票,價值781,092.42美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以在美國證券交易委員會網站上找到。
Bruce Keyt also recently made the following trade(s):
布魯斯·凱伊特最近還進行了以下交易:
- On Tuesday, September 6th, Bruce Keyt sold 5,000 shares of IGM Biosciences stock. The shares were sold at an average price of $19.06, for a total transaction of $95,300.00.
- On Friday, August 19th, Bruce Keyt sold 8,700 shares of IGM Biosciences stock. The shares were sold at an average price of $22.82, for a total transaction of $198,534.00.
- On Monday, August 22nd, Bruce Keyt sold 6,300 shares of IGM Biosciences stock. The stock was sold at an average price of $20.71, for a total transaction of $130,473.00.
- 9月6日,星期二,Bruce KEYT出售了5,000股IGM Biosciences股票。這些股票以19.06美元的平均價格出售,總成交金額為95,300.00美元。
- 8月19日,星期五,Bruce KEYT出售了8,700股IGM Biosciences股票。這些股票以22.82美元的平均價格出售,總成交金額為198,534.00美元。
- 8月22日,星期一,Bruce KEYT出售了6,300股IGM Biosciences的股票。該股以20.71美元的平均價格出售,總成交金額為130,473.00美元。
IGM Biosciences Stock Performance
IGM Bioscions股票表現
IGMS stock opened at $21.25 on Friday. The stock has a market capitalization of $903.76 million, a P/E ratio of -3.74 and a beta of -0.32. IGM Biosciences, Inc. has a one year low of $12.67 and a one year high of $76.20. The company has a 50 day moving average price of $20.04 and a two-hundred day moving average price of $18.47.
IGMS股票上週五開盤報21.25美元。該股市值為9.0376億美元,市盈率為-3.74,貝塔係數為-0.32。IGM Biosciences,Inc.的一年低點為12.67美元,一年高位為76.20美元。該公司的50日移動均線價格為20.04美元,200日移動均線價格為18.47美元。
Hedge Funds Weigh In On IGM Biosciences
對衝基金參與IGM生物科學
Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Hong Kong Ltd acquired a new position in shares of IGM Biosciences during the 4th quarter valued at $34,000. Amalgamated Bank acquired a new position in IGM Biosciences in the 1st quarter worth $36,000. US Bancorp DE lifted its holdings in IGM Biosciences by 608.4% in the 1st quarter. US Bancorp DE now owns 2,437 shares of the company's stock worth $65,000 after buying an additional 2,093 shares in the last quarter. Captrust Financial Advisors acquired a new position in IGM Biosciences in the 2nd quarter worth $50,000. Finally, American International Group Inc. lifted its holdings in IGM Biosciences by 15.0% in the 2nd quarter. American International Group Inc. now owns 4,684 shares of the company's stock worth $84,000 after buying an additional 612 shares in the last quarter. Institutional investors and hedge funds own 41.20% of the company's stock.
對衝基金和其他機構投資者最近對他們在該業務中的頭寸進行了調整。Point72 Hong Kong Ltd於第四季度收購了價值34,000美元的IGM Biosciences股票的新頭寸。合併銀行在第一季度收購了IGM Biosciences的一個新頭寸,價值3.6萬美元。美國Bancorp DE在第一季度增持了IGM Biosciences 608.4%的股份。US Bancorp DE現在擁有2437股該公司股票,價值6.5萬美元,此前在上個季度又購買了2093股。CapTrust Financial Advisors在第二季度收購了IGM Biosciences的一個新頭寸,價值5萬美元。最後,美國國際集團(American International Group Inc.)在第二季度增持了IGM Biosciences 15.0%的股份。美國國際集團目前持有該公司4,684股股票,價值84,000美元,此前該公司在上個季度又購買了612股。機構投資者和對衝基金持有該公司41.20%的股票。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
IGMS has been the subject of a number of recent research reports. Guggenheim dropped their price objective on shares of IGM Biosciences to $40.00 in a research note on Monday, August 15th. Bank of America initiated coverage on shares of IGM Biosciences in a research note on Monday, August 29th. They set a "buy" rating and a $34.00 price objective for the company. HC Wainwright dropped their price objective on shares of IGM Biosciences from $59.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Truist Financial dropped their price objective on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating for the company in a research note on Tuesday, August 23rd. Finally, Robert W. Baird lowered their target price on shares of IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating for the company in a research note on Wednesday, June 1st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.00.
政府間海洋生態系統是最近一些研究報告的主題。古根海姆在8月15日星期一的一份研究報告中將IGM Biosciences的股票目標價下調至40.00美元。美國銀行在8月29日星期一的一份研究報告中啟動了對IGM Biosciences股票的報道。他們為該公司設定了“買入”評級和34.00美元的目標價。5月17日,週二,HC Wainwright在一份研究報告中將IGM Biosciences的股票目標價從59.00美元下調至58.00美元,併為該公司設定了“買入”評級。Truist Financial在8月23日(星期二)的一份研究報告中將IGM Biosciences的股票目標價從74.00美元下調至37.00美元,併為該公司設定了“買入”評級。最後,羅伯特·W·貝爾德在6月1日星期三的一份研究報告中將IGM Biosciences的股票目標價從46.00美元下調至31.00美元,併為該公司設定了“跑贏大盤”的評級。兩名股票研究分析師對該股的評級為持有,七名分析師對該公司的評級為買入。根據MarketBeat的數據,該公司目前的共識評級為“適度買入”,共識目標價為53.00美元。
IGM Biosciences Company Profile
IGM生物科學公司簡介
(Get Rating)
(獲取評級)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
IGM生物科學公司是一家生物技術公司,開發用於治療癌症、傳染病、自身免疫性疾病和炎症性疾病的免疫球蛋白M(IgM)抗體。該公司的主要候選產品是IGM-2323,這是一種雙特異性IgM抗體,正處於第二階段臨牀試驗,用於治療復發/難治性B細胞非霍奇金淋巴瘤(NHL)患者。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於IGM生物科學的研究報告(IGMS)
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受IGM《生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對IGM Biosciences和相關公司的最新新聞和分析師評級的每日簡明摘要。